Abstract
It has been suggested that one of the reasons for failure to achieve local tumour control in some clinical radiotherapy schedules is the presence of hypoxic cells1,2. Although resistant to radiation it has been found that these cells are also sensitive to certain drugs3 and hyperthermia4. As a result, attempts are now being made to actually increase the level of tumour hypoxia before subsequent exposure to these hypoxic cell cytotoxic agents.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S. Diseche, Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy, Radiother. Oncol., 3:97, (1985).
R. S. Bush, The significance of anaemia in clinical radiation therapy, Int. J. Radiât. Oncol. Biol. Phys., 12: 2047 (1986).
B. A. Teicher, J. S. Lazo, and A. C. Sartorelli, Classification of antineoplastic agents by their selective toxicities towards oxygenated and hypoxic tumor cells, Cancer Res., 41:73 (1981).
H. D. Suit and L. E. Gerweck, Potential for hyperthermia and radiation therapy, Cancer Res., 39:2290 (1979).
M. Nickerson, Vasodilator drugs, in: “The Pharmacological Basis of Therapeutics”, 5th edn, L. S. Goodman and A. Gilman, eds., MacMillan, New York (1975).
F. J. Sutton, Vasodilator therapy, Am. J. Med., 80:54 (1986).
D. J. Chaplin and B. Acker, The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: Evidence for therapeutic gain, Int. J. Radiat. Oncol. Biol. Phys., 13:579 (1987).
J. M. Brown, Exploitation of bioreductive agents with vasoactive drugs, in: “Proceedings of the 8th International Congress of Radiation Research”, vol. 2, E. M. Fielden, J. F. Fowler, J. H. Hendry, and D. Scott, eds., Taylor and Francis, London (1987).
M. R. Horsman, K. L. Christensen, and J. Overgaard, Hydralazine induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo, Int. J. Hyperthermia, 5:123 (1989).
R. Sridhar, and R. Sutherland, Hyperthermic potentiation of cytotoxicity of Ro-07-0582 in multicell spheroids, Int. J. Radiat. Oncol. Biol. Phys., 2:531 (1977).
I. J. Stratford and G. E. Adams, Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro, Br. J. Cancer, 35: 307 (1977).
N. M. Bleehen, D. J. Honess, and J. E. Morgan, Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumor, Br. J. Cancer, 35:299 (1977).
J. Overgaard, Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo, Int. J. Radiat. Oncol. Biol. Phys., 6:1507 (1980).
T. Kamura, O. S. Nielsen, J. Overgaard, and A. H. Andersen,Development of thermotolerance during fractionated hyperthermia in a solid tumor in vivo, Cancer Res., 42:1744 (1982).
L. A. Sapirstein, Regional blood flow by fractional distribution of indicators, Am. J. Physiol., 193:161 (1958).
P. L. Olive, R. E. Durand, and D. J. Chaplin, Cytotoxicity of RSU 1069 in spheroids and murine tumours, Int. J. Radiat. Oncol. Biol. Phys., 13:1361 (1987).
D. J. Honess, P. Workman, J. E. Morgan, and N. M. Bleehen, Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetised mouse, Br. J. Cancer, 41: 529 (1980).
M. I. Walton, N. M. Bleehen, and P. Workman, Effects of localized tumour hyperthermia on pimonidazole (Ro 03–8799) pharmacokinetics in mice, Br. J. Cancer, 59:667 (1989).
C. W. Song, Effect of local hyperthermia on blood flow and raicroenvironment: A review, Cancer Res., 44: 4721S (1984).
P. Workman and M. I. Walton, Pharmacology of the mixed-function radio- and chemosensitizers CB1954 and RSU-1069, Int. J. Radiat. Oncol. Biol. Phys., 10:1307 (1984).
H. D. Suit, Hyperthermia in the treatment of tumors, in: “Proc. Int. Symp. Cancer Therapy by Hyperthermia and Radiation”, American College of Radiology, Washington (1975).
S. A. Hill and J. Denekamp, The effect of vascular occlusion on the thermal sensitization of a mouse tumour, Br. J. Radiol., 51:997 (1978).
M. R. Horsman, J. Overgaard, and D. J. Chaplin, The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay, Acta Oncol., 27:861 (1988).
J. C. Lindegaard and J. Overgaard, Factors of importance for the development of the step-down heating effect in a C3H mammary carcinoma in vivo, Int. J. Hyperthermia, 3:79 (1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Horsman, M.R., Christensen, K.L., Chaplin, D.J., Overgaard, J. (1990). Improved Treatment of Tumours in vivo by Combining the Bioreductive Drug RSU-1069, Hydralazine and Hyperthermia. In: Adams, G.E., Breccia, A., Fielden, E.M., Wardman, P. (eds) Selective Activation of Drugs by Redox Processes. NATO ASI Series, vol 198. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3768-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3768-7_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6679-9
Online ISBN: 978-1-4615-3768-7
eBook Packages: Springer Book Archive